Creo Medical Group Plc

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB00BZ1BLL44
GBP
0.10
0 (0.5%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor Management Efficiency with a low ROE of 0%

  • The company has reported losses. Due to this company has reported negative ROE
2

Poor long term growth as Operating profit has grown by an annual rate -5.53% of over the last 5 years

 
3

Flat results in Jun 24

4

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

GBP 42 Million ()

stock-summary
P/E

11.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.27

stock-summary
Return on Equity

7.55%

stock-summary
Price to Book

0.68

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-22.85%
0%
-22.85%
6 Months
-35.68%
0%
-35.68%
1 Year
-35.19%
0%
-35.19%
2 Years
-68.83%
0%
-68.83%
3 Years
-72.01%
0%
-72.01%
4 Years
-92.37%
0%
-92.37%
5 Years
-93.75%
0%
-93.75%

Creo Medical Group Plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
79.03%
EBIT Growth (5y)
-5.53%
EBIT to Interest (avg)
-26.54
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.10
Sales to Capital Employed (avg)
0.32
Tax Ratio
10.76%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
0.80
EV to EBIT
-1.38
EV to EBITDA
-1.53
EV to Capital Employed
0.73
EV to Sales
1.88
PEG Ratio
0.09
Dividend Yield
NA
ROCE (Latest)
-53.14%
ROE (Latest)
7.55%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Creo Medical Group Plc"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2022 is 7.94% vs 168.09% in Dec 2021",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2022 is -9.35% vs -21.18% in Dec 2021",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "27.20",
          "val2": "25.20",
          "chgp": "7.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-27.70",
          "val2": "-27.40",
          "chgp": "-1.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "-0.20",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-26.90",
          "val2": "-24.60",
          "chgp": "-9.35%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,133.90%",
          "val2": "-1,190.70%",
          "chgp": "5.68%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Dec'22stock-summary
Dec'22
Dec'21
Change(%)
Net Sales
27.20
25.20
7.94%
Operating Profit (PBDIT) excl Other Income
-27.70
-27.40
-1.09%
Interest
0.20
0.20
Exceptional Items
-0.00
-0.20
100.00%
Consolidate Net Profit
-26.90
-24.60
-9.35%
Operating Profit Margin (Excl OI)
-1,133.90%
-1,190.70%
5.68%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2022 is 7.94% vs 168.09% in Dec 2021

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2022 is -9.35% vs -21.18% in Dec 2021

stock-summaryCompany CV
About Creo Medical Group Plc stock-summary
stock-summary
Creo Medical Group Plc
Pharmaceuticals & Biotechnology
Creo Medical Group plc is a United Kingdom-based medical device company. The Company focuses on the field of surgical endoscopy. The Company focuses on the development and commercialization of minimally invasive surgical devices, initially in the area of gastrointestinal (GI) surgery and lung cancer. The Company has developed CROMA, which is an electrosurgical platform that can deliver microwave and bipolar radiofrequency through a single accessory port. The Company's surgical system CROMA combines bipolar radiofrequency for localized cutting and microwave energy for controlled coagulation, which provides physicians with simplified and controlled surgical solutions. The Company's pipeline portfolio of instruments is targeted at three therapeutic endoscopic specialties: lower GI; lung/bronchoscopy and upper GI.
Company Coordinates stock-summary
Company Details
Unit 2 Beaufort Park,, Beaufort Park Way , CHEPSTOW None : NP16 5UH
stock-summary
Tel: 44 1291 606005
stock-summary
Registrar Details